[Significance of docetaxel in the chemotherapy of hormone-refractory prostate cancer]

Onkologie. 2003 Dec;26 Suppl 7:37-40. doi: 10.1159/000076173.
[Article in German]

Abstract

Docetaxel (Taxotere) is a taxoid derived from the European yew tree, taxus baccata. In 4 phase-II studies docetaxel has important single agent activity with an overall prostate-specific antigen response rate of 42% in hormone refractory prostate cancer. Other phase-II studies suggest that the addition of estramustine to docetaxel results in a higher response rate but also in an increased toxicity. At present Docetaxel with and without estramustine is being evaluated in phase-III studies that will provide definitive information about its role in hormone refractory prostate cancer.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Antineoplastic Agents, Phytogenic / administration & dosage*
  • Antineoplastic Agents, Phytogenic / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / toxicity
  • Biomarkers, Tumor / blood
  • Clinical Trials as Topic
  • Docetaxel
  • Estramustine / administration & dosage
  • Estramustine / toxicity
  • Humans
  • Male
  • Neoplasm Staging
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology
  • Taxoids / administration & dosage*
  • Taxoids / toxicity

Substances

  • Antineoplastic Agents, Phytogenic
  • Biomarkers, Tumor
  • Taxoids
  • Docetaxel
  • Estramustine
  • Prostate-Specific Antigen